Fundraising FoxF-Prime Capital — 2015 Investments
5 investments dated 2015 · listed companies and verified rows first · show all
Dimension Therapeutics was a Cambridge, Massachusetts biopharmaceutical company developing AAV-based gene therapies for rare liver-associated metabolic diseases like hemophilia, OTC deficiency, and glycogen storage disease.
Cambridge, US
Annalisa Jenkins(Executive Officer, Director)
BoardBenjamin Auspitz(Director)Donald J. Hayden(Director)Allan Fox(Director)
Co-investorsNew Leaf Venture PartnersOrbiMed
Intuition is a decentralized knowledge network with a native blockchain and token-curated knowledge graph for "Information Finance," turning facts, claims, and signals into verifiable, tradable data assets.
AI & Machine LearningCrypto & Web3Data & InfrastructurePortland, US
Khalil Zaidan(LLC Manager)Andrew Cox(Founder)in
Co-investorsPolymorphic CapitalStateless VenturesWWVenturesAdditionAndreessen HorowitzCoatue Management+7 more
Kensho is an AI innovation division within S&P Global that develops generative and agentic AI systems for financial intelligence and enterprise platforms.
AI & Machine LearningData & InfrastructureEnterprise SoftwareFintechCambridge, US
Daniel Nadler(Founder)inPeter Kruskall(Founder)Bhavesh Dayalji(CEO & S&P Global Chief AI Officer)in
Co-investorsBreyer CapitalComcast VenturesGen CapitalGV (Google Ventures)In-Q-TelGeneral Catalyst+3 more
.png)
ReadMe lets companies build interactive developer hubs and documentation portals that combine support, tutorials, guides, and API exploration.
Cloud ComputingDeveloper ToolsEnterprise SoftwareSaaSSector AgnosticNew York City, US
Gregory Koberger(Founder)inGabriel Dillon(Developer Evangelist)Mary Hoffbeck(People Ops)Dominic Harrington(Engineering Manager)Tony Li(Head of Design)Nick Starkey(Hiring Manager)
Co-investorsAccelGreat Oaks Venture CapitalHeavybitMission and MarketSoma CapitalY Combinator+5 more
.jpeg)
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.